Birgit E. P. J. Vriens

Author

Also Known As

B. E. P. J. Vriens, B. Vriens, B.E.P.J. Vriens, Birgit E.P.J. Vriens, Birgit E. P. J. Vriens, Birgit E. Vriens, Birgit E.P. Vriens, Birgit E.P.J. Vriens, Birgit EPJ Vriens, Birgit Vriens

Publications

942

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Catharina Ziekenhuis Maastricht University Maastricht University Medical Centre Elkerliek Ziekenhuis

About

Birgit E. P. J. Vriens is an author at Radboud University Nijmegen specializing in oncology, breast cancer, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	141
2	Health Sciences	4	4	205
3	Engineering	1	1	79
4	Applied Physiology	1	1	78
5	Exercise Physiology	1	1	78

Birgit E. P. J. Vriens

Publications

542

Citations

H-Index

Page 1

	Year	Citations
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer Birgit E. P. J. Vriens, Bart de Vries, Marc B. I. Lobbes, European Journal of Cancer Medical UltrasoundBreast OncologyEngineeringOncologic ImagingMedical Imaging	2015	79
Effect of dehydration on gastrointestinal function at rest and during exercise in humans Michiel A. van Nieuwenhoven, Birgit E. P. J. Vriens, Robert J. Brummer, European Journal of Applied Physiology Physical ActivityKinesiologyExerciseExercise PhysiologyPhysiology	2000	78
Clinical examination and non‐invasive screening tests in the diagnosis of peripheral artery disease in people with diabetes‐related foot ulceration Birgit E. P. J. Vriens, Fabrizio D’Abate, Baris Ata Ozdemir, Diabetic Medicine	2018	59
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer Birgit E. P. J. Vriens, Maureen J.B. Aarts, Bart de Vries, European Journal of Cancer Breast OncologyOncologyMedicineNeoadjuvant TreatmentBreast Cancer	2013	43
Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls Romy Aarnoutse, Lars E. Hillege, Janine Ziemons, Cancers	2021	39
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy Romy Aarnoutse, Janine Ziemons, Lars E. Hillege, npj Breast Cancer	2022	39
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) Ayoub Charehbili, Saskia van de Ven, Vincent T.H.B.M. Smit, Annals of Oncology Zoledronic AcidBreast OncologyMedicinePharmacologyNeozotac Trial	2014	38
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst, The Lancet Oncology Neoadjuvant Chemotherapy DurationBreast OncologyMedical ImagingMedicineMri-guided Optimisation	2024	36
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry Marissa Meegdes, Sandra M. E. Geurts, Frans Erdkamp, The Lancet Regional Health - Europe	2023	30
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer Birgit E. P. J. Vriens, Ingeborg J. H. Vriens, Maureen J.B. Aarts, Breast Cancer Research and Treatment	2017	17

Page 1